Sermorelin
Also known as: GRF 1-29, GHRH 1-29 acetate
Molecular Overview
Sermorelin (GHRH 1-29) is the shortest fully active fragment of GHRH and was historically used as a diagnostic and therapeutic agent before commercial withdrawal; it remains a common reference compound in secretagogue research.
Mechanistic Background
Engages the GHRH receptor in pituitary models, mirroring endogenous GHRH fragment activity.
What Researchers Study
Extensive historical clinical and preclinical literature exists for GHRH 1-29.
Evidence Landscape
Current evidence level: FOUNDATIONAL. Preclinical evidence does not equate to demonstrated human efficacy.
Research Limitations
Original pharmaceutical products were discontinued for commercial reasons; research-market material is not a drug product.
Scientific References
Research Use Only
Molecularix Biolabs provides research materials for legitimate laboratory research. Information in this Research Library is provided for educational and scientific reference purposes and is not medical advice, treatment guidance, or a recommendation for human or veterinary use.